G&E Herbal Biotechnology Co (ROCO:4911) Cyclically Adjusted Revenue per Share: NT$1.48 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4911 G&E Herbal Biotechnology Co Ltd ROCO:4911
62 GF Score
Price NT$28.25
GF Value NT$59.69
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is G&E Herbal Biotechnology Co Cyclically Adjusted Revenue per Share?

G&E Herbal Biotechnology Co ROCO:4911 -0.88% 62 Cyclically Adjusted Revenue per Share is NT$1.48 as of Mar. 2026. GuruFocus rates ROCO:4911 with a GF Score™ of 62/100 and a GF Value™ of NT$59.69 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

G&E Herbal Biotechnology Co's adjusted revenue per share for the three months ended in Mar. 2026 was NT$0.461. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$1.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, G&E Herbal Biotechnology Co's average Cyclically Adjusted Revenue Growth Rate was 25.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 31.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of G&E Herbal Biotechnology Co was 31.40% per year. The lowest was 5.30% per year. And the median was 19.90% per year.

As of today (2026-08-12), G&E Herbal Biotechnology Co's current stock price is NT$28.25. G&E Herbal Biotechnology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$1.48. G&E Herbal Biotechnology Co's Cyclically Adjusted PS Ratio of today is 19.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of G&E Herbal Biotechnology Co was 98.51. The lowest was 18.85. And the median was 48.70.


G&E Herbal Biotechnology Co  (ROCO:4911) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

G&E Herbal Biotechnology Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=28.25/1.48
=19.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of G&E Herbal Biotechnology Co was 98.51. The lowest was 18.85. And the median was 48.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


G&E Herbal Biotechnology Co Cyclically Adjusted Revenue per Share Related Terms


G&E Herbal Biotechnology Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for G&E Herbal Biotechnology Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

G&E Herbal Biotechnology Co Cyclically Adjusted Revenue per Share Chart

G&E Herbal Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.63 0.83 1.06 1.43

G&E Herbal Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.28 1.38 1.43 1.48

ROCO:4911 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, G&E Herbal Biotechnology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


G&E Herbal Biotechnology Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G&E Herbal Biotechnology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where G&E Herbal Biotechnology Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4911
62GF Score
G&E Herbal Biotechnology Co Ltd ROCO:4911
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

G&E Herbal Biotechnology Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, G&E Herbal Biotechnology Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.461/330.2130*330.2130
=0.461

Current CPI (Mar. 2026) = 330.2130.

G&E Herbal Biotechnology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.157 241.018 0.215
201609 0.085 241.428 0.116
201612 0.121 241.432 0.165
201703 0.047 243.801 0.064
201706 0.191 244.955 0.257
201709 0.028 246.819 0.037
201712 0.029 246.524 0.039
201803 0.001 249.554 0.001
201806 0.001 251.989 0.001
201809 0.007 252.439 0.009
201812 0.024 251.233 0.032
201903 0.031 254.202 0.040
201906 0.079 256.143 0.102
201909 0.076 256.759 0.098
201912 0.071 256.974 0.091
202003 0.059 258.115 0.075
202006 0.073 257.797 0.094
202009 0.141 260.280 0.179
202012 0.135 260.474 0.171
202103 0.120 264.877 0.150
202106 0.051 271.696 0.062
202109 0.119 274.310 0.143
202112 0.075 278.802 0.089
202203 0.105 287.504 0.121
202206 0.106 296.311 0.118
202209 0.276 296.808 0.307
202212 0.437 296.797 0.486
202303 0.592 301.836 0.648
202306 0.647 305.109 0.700
202309 0.694 307.789 0.745
202312 0.709 306.746 0.763
202403 0.804 312.332 0.850
202406 0.803 314.175 0.844
202409 0.897 315.301 0.939
202412 1.041 315.605 1.089
202503 1.158 319.799 1.196
202506 1.068 322.561 1.093
202509 1.165 324.800 1.184
202512 1.001 324.054 1.020
202603 0.461 330.213 0.461

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$1.48 mean?
G&E Herbal Biotechnology Co (ROCO:4911) has a Cyclically Adjusted Revenue per Share of NT$1.48 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on G&E Herbal Biotechnology Co and its competitors.
Is G&E Herbal Biotechnology Co's Cyclically Adjusted Revenue per Share too high?
G&E Herbal Biotechnology Co's current Cyclically Adjusted Revenue per Share is NT$1.48. Overall, G&E Herbal Biotechnology Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does G&E Herbal Biotechnology Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
G&E Herbal Biotechnology Co's Cyclically Adjusted Revenue per Share of NT$1.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on G&E Herbal Biotechnology Co and its competitors. G&E Herbal Biotechnology Co's current Cyclically Adjusted Revenue per Share is NT$1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is G&E Herbal Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, G&E Herbal Biotechnology Co (ROCO:4911) is currently considered Possible Value Trap. The stock's GF Value™ is NT$59.69, compared to a current price of NT$28.25 — trading 52.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$1.48. G&E Herbal Biotechnology Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For G&E Herbal Biotechnology Co (ROCO:4911), the current Cyclically Adjusted Revenue per Share is NT$1.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is G&E Herbal Biotechnology Co (ROCO:4911) Overvalued in 2026?

Based on GuruFocus' analysis, G&E Herbal Biotechnology Co stock appears to be undervalued. The current stock price of NT$28.25 is trading 52.7% below its estimated GF Value™ of NT$59.69. GuruFocus considers G&E Herbal Biotechnology Co to be Possible Value Trap.

Key valuation signals for ROCO:4911:

  • Cyclically Adjusted Revenue per Share: NT$1.48
  • GF Value™: NT$59.69 vs. price of NT$28.25 (52.7% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


G&E Herbal Biotechnology Co Business Description

Address No. 92, Keji 5th Road, Annan District, Tainan, TWN, 709015
G&E Herbal Biotechnology Co Ltd is a Taiwan-based biopharmaceutical company. It specializes in the production of Western conventional drugs, Chinese traditional drugs, unclassified food, cosmetics, and health products. The company is focused on botanical extraction technology and products. Its products include botanical extract toner, total moisture conditioning cream, whitening clear cream, and firming essence cream.
62GF Score

Get the complete analysis for ROCO:4911

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.25
Price
NT$59.69
GF Value